Form 4 for PRLD Prelude Therapeutics Inc
Accepted 2024-12-20 00:00:00 ET · period of report 2024-12-18 · accession 0001562180-24-008531 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-20 | 2024-12-18 | PRLD | Vaddi Krishna | CEO, Dir | P - Purchase | $0.93 | +100.0K | 1.17M | +9% | +$93.0K | |
| I | 2024-12-20 | 2024-12-19 | PRLD | Vaddi Krishna | CEO, Dir | P - Purchase | $0.89 | +6,888 | 127.6K | +6% | +$6,130 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-18 | P | A | 100,000 | $0.93 | 1,167,275 | D See footnote | — | — | (F1) 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.89 to $1.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. (F2) The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
| 2 | Common | Common Stock | 2024-12-19 | P | A | 6,888 | $0.89 | 127,553 | I | — | — |